Position in NERV
as of Mar 31, 2026
· filed May 20, 2026
Position Value
$26,044,550
+$8,667,108 QoQ
Shares Held
4,322,747
0.0% QoQ
Ownership
9.28%
of shares outstanding
% of Portfolio
2.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NERV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Vivo Capital, LLC holds $1,160,013,312 across 42 Biotechnology names. NERV ranks #14 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ERAS |
Erasca, Inc.
|
12,151,480 | $196,610,946 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
338,895 | $109,188,580 | |
| 3 | TERN |
Terns Pharmaceuticals, Inc.
|
1,334,418 | $70,350,516 | |
| 4 | TRVI |
Trevi Therapeutics, Inc.
|
5,094,668 | $60,779,389 | |
| 5 | DBVT |
DBV Technologies S.A.
|
2,667,569 | $55,725,516 | |
| 6 | CMPX |
Compass Therapeutics, Inc.
|
9,545,466 | $50,495,515 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
2,154,780 | $45,077,997 | |
| 8 | SABS |
SAB Biotherapeutics, Inc.
|
11,420,000 | $43,738,600 |
All Filings in NERV
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $26,044,550 | 4,322,747 | Shares | Sole | 2026-05-20 | |
| 2025-12-31 | $17,377,442 | 4,322,747 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||